SCHEMBL794138

SCHEMBL794138

Fc1ccc(-c2cc3cnc(-c4ccccc4)nc3s2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 2/20 0.47
ADORA2A P29274 1/20 0.47
FGFR1 P11362 2/20 0.45
MAPT P10636 4/20 0.43
RAB9A P51151 2/20 0.43
PLCG2 P16885 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
GGPS1 O95749 1/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
KDM4E B2RXH2 2/20 0.40
LMNA P02545 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
ALDH1A1 P00352 1/20 0.39
ALOX5 P09917 1/20 0.38
HPGDS O60760 1/20 0.38
HSD17B1 P14061 1/20 0.38
HSD17B2 P37059 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL798266 0.77 PTGS2 (0.47) ADORA1ADORA2AFGFR1MAPTSMN1; SMN2
SCHEMBL38658460 0.73 FGFR1 (0.43) FGFR1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL18341986 0.71 CYP2A6 (0.46) FGFR1MAPTRAB9AMEN1KMT2A
SCHEMBL16902583 0.71 NPC1 (0.38) ADORA1ADORA2AMAPTRAB9ASMN1; SMN2
SCHEMBL27991340 0.69 MAPT (0.51) MAPTRAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL5268082 0.69 ALDH1A1 (0.48) ADORA1ADORA2AFGFR1MAPTRAB9A
SCHEMBL23733792 0.69 MAPT (0.50) ADORA1ADORA2AMAPTRAB9ASMN1; SMN2
SCHEMBL27799881 0.69 DPP4 (0.46) ADORA1ADORA2AMAPTRAB9AMEN1
SCHEMBL656735 0.69 IKBKB (0.44) ADORA1ADORA2AMAPTRAB9ASMN1; SMN2
SCHEMBL28157573 0.68 CYP1A2 (0.63) ADORA2AMAPTRAB9ASMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2616077-A1 ANTI-CANCER ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) 2013-07-24 EP disclosed
WO-2012035423-A1 ANTI-CANCER ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2012-03-22 WO disclosed